Rion Vet

What Rion Vet does

Rion Vet is a wholly-owned subsidiary of RION, established in 2025 to commercialize veterinary applications of RION's proprietary platelet-derived exosome technology platform. The company's core technology is Purified Exosome Product™ (PEP™), a lyophilized biologic drug substance containing up to two trillion regenerative exosomes per vial, derived from platelets and manufactured using RION's proprietary scalable isolation process. PEP™ has demonstrated regenerative capability across multiple tissue types (skin, heart, muscle, tendon, lung, nerve, vaginal mucosa) in preclinical and clinical studies, and supports multiple routes of administration including topical, intra-articular, IV, IM, and nebulizer applications. The veterinary vertical is pursued as a shorter regulatory pathway relative to human therapeutics, allowing the company to leverage RION's clinical-stage platform with lower development cost and faster time-to-market.

Rion Vet is led by CEO Mark Herthel and operates with 1-10 employees out of RION's Rochester, Minnesota headquarters at 202 4th Street SW, Suite 480, co-located with the parent company's expanded manufacturing facility in the Mayo Clinic ecosystem. The company raised a $15 million Series A in late 2025 led by Five Elms Capital to fund veterinary pipeline development. Rion Vet benefits from inherited infrastructure including RION's GMP manufacturing capabilities, the Lonza manufacturing scale-up partnership, and Blood Centers of America's platelet supply chain — assets that would be cost-prohibitive to replicate independently.

The business model is currently pre-revenue: Rion Vet has no disclosed pricing, no named customers, and no announced veterinary clinical trials or commercial distribution channels. Future revenue is expected to derive from licensing/royalty arrangements, direct therapeutic product sales through veterinary specialty channels, and potential contract manufacturing leveraging RION's Rochester facility. Customer segments have not been formally defined beyond the implicit specialty veterinary practice and pet owner end-user base.

Name

Rion Vet

Legal name

RION

Website

https://riontx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Rion Vet is a wholly-owned subsidiary of RION, established in 2025 to commercialize veterinary applications of the parent company's proprietary platelet-derived exosome platform (PEP™). The company raised a $15 million Series A led by Five Elms Capital to develop regenerative medicine therapeutics for animal health.

Ownership category

akta.pro rank

Product category

Veterinary Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Veterinary Services (541940)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Exosome & Extracellular Vesicle (EV) Therapeutics (HLAMANAE)

akta.pro secondary industries

Companion Animal Therapeutics (Rx) (HLAMAEAA), Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK), Point-of-Care Regenerative Kits & Devices (Processing/Delivery) (HLAMANAK)

Keywords

• Veterinary regenerative medicine
• Exosome therapeutics
• Platelet-derived biologics
• Veterinary biotech
• Animal tissue repair

Headquarters

HQ city

Rochester

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Therapeutic Product Sales: Future commercialization of PEP™ as a regenerative therapeutic for wound healing, cardiovascular disease, musculoskeletal disorders, and other indications through clinical development and FDA approval pathway.
2. Licensing and Partnerships: Partnership with Lonza for manufacturing scale-up, and strategic partnerships for co-development of exosome-based therapies. INTENT Biologics subsidiary for late-stage clinical development in inflammation and immunology.
3. Manufacturing Services: GMP manufacturing capabilities for exosome-based therapeutics, with expanded facility in Rochester, Minnesota supporting both internal pipeline and potential contract manufacturing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Rion Vet is a wholly-owned subsidiary of RION focused on veterinary applications of exosome-based regenerative therapeutics. Its core offering is the veterinary application of Purified Exosome Product (PEP™), a biologic drug substance containing trillions of platelet-derived regenerative exosomes manufactured as a lyophilized powder. The product supports multiple routes of administration (topical, intra-articular, IV, IM, nebulizer) for veterinary indications including wound healing, musculoskeletal disorders, and tissue regeneration.

Product overview

RION is a clinical-stage regenerative medicine company offering a platform of exosome-based therapeutics. The core product is Purified Exosome Product™ (PEP™), a novel drug substance containing trillions of platelet-derived regenerative exosomes. PEP™ is manufactured using RION's proprietary platform technology that enables scalable production of regenerative exosomes. The platform also serves as a drug delivery system capable of encapsulating mRNA, siRNA, DNA, and small molecules. RION's clinical programs focus on wound healing (diabetic foot ulcers), musculoskeletal diseases (knee osteoarthritis), cardiovascular conditions, and pulmonary therapeutics, with ongoing Phase 1b and Phase 2 clinical studies. The company was established out of the Mayo Clinic Employee Entrepreneurial Program in 2017 and has 20 peer-reviewed publications supporting its technology.

Differentiator

Problem solved

Functional benefit

Brands

• Purified Exosome Product (PEP): RION's innovative drug substance containing trillions of platelet-derived regenerative exosomes, used for tissue regeneration applications across multiple therapeutic areas including skin, heart, muscle, tendon, lung, nerve, and vaginal mucosa.

Products and services

• Purified Exosome Product (PEP™) PEP™ is a novel biologic drug substance containing up to 2 trillion platelet-derived regenerative exosomes per vial, manufactured as a lyophilized powder with 24-month room-temperature shelf life. For Rion Vet, this product is being applied to veterinary indications including wound healing, musculoskeletal disorders, and tissue regeneration in companion animals. The product supports multiple administration routes (topical, intra-articular, IV, IM, nebulizer).

Quantifiable outcome

• PEP with fibrin sealant produced greater functional recovery (isometric tetanic force) compared to untreated controls in volumetric muscle loss rat model at 90 days
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• LonzacoreStrategic or Co-development Partner · 23 September 2025RION engaged Lonza to scale manufacturing of exosome-based therapeutics. Lonza, a leading contract development and manufacturing organization (CDMO), will support RION in scaling up GMP manufacturing capabilities for PEP™ to meet clinical and commercial demand.
• INTENT BiologicscoreStrategic or Co-development Partner · 9 September 2025RION launched INTENT Biologics as a subsidiary to develop late-stage clinical exosome-based therapies in inflammation and immunology. Appointed biopharma veteran Suneet Varma as CEO to lead the subsidiary's development programs.
• Mayo CliniccoreStrategic or Co-development PartnerRION was established out of the Mayo Clinic Employee Entrepreneurial Program in 2017. Technology originated from Mayo Clinic Van Cleve Cardiac Regenerative Medicine Program. Ongoing research collaboration and access to clinical expertise.
• U.S. Army Medical Research Institute for Chemical DefensemajorStrategic or Co-development PartnerCollaborative partner in $2.4M Department of Defense award to advance exosome-based research in pulmonary therapeutics. Part of broader defense/health research initiative.
• Blood Centers of AmericamajorStrategic or Co-development PartnerPartnership for supply of platelet-derived starting material for exosome manufacturing. Ensures sustainable and quality-controlled source of raw materials.
• Medical AlleyminorStrategic or Co-development PartnerMember of Medical Alley ecosystem, Minnesota's leading healthcare and biotechnology industry cluster, providing networking and ecosystem support.

Scale indicators6 records

Recent moves2 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php?id=100090739834729
• LinkedInlinkedin.com/company/rion-vet
• Instagraminstagram.com/rion_tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rion Vet